Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | TACR3 | P29371 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7309037 | 0.87 | L3MBTL1 (1.00) | L3MBTL1HSD11B1ALDH1A1POLBKDM4E | |
| SCHEMBL27547326 | 0.85 | L3MBTL1 (0.79) | L3MBTL1HSD11B1ALDH1A1POLBKDM4E | |
| SCHEMBL14495101 | 0.85 | PKM (0.59) | L3MBTL1ALDH1A1POLBMAPTPKM | |
| SCHEMBL24663632 | 0.85 | L3MBTL1 (0.73) | L3MBTL1HSD11B1ALDH1A1POLBKDM4E | |
| SCHEMBL8269181 | 0.85 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1MAPTPKM | |
| SCHEMBL15014500 | 0.84 | L3MBTL1 (0.71) | L3MBTL1HSD11B1ALDH1A1POLBKDM4E | |
| SCHEMBL15498614 | 0.84 | ALDH1A1 (0.78) | L3MBTL1HSD11B1ALDH1A1POLBKDM4E | |
| SCHEMBL22549554 | 0.84 | L3MBTL1 (0.71) | L3MBTL1HSD11B1ALDH1A1POLBKDM4E | |
| SCHEMBL6210602 | 0.83 | L3MBTL1 (0.75) | L3MBTL1HSD11B1ALDH1A1POLBKDM4E | |
| SCHEMBL12424606 | 0.81 | L3MBTL1 (0.68) | L3MBTL1HSD11B1ALDH1A1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | L3MBTL1 1003/4885HSD11B1 1352/4885ALDH1A1 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.